BioCentury
ARTICLE | Clinical News

House dust mite (HDM) sublingual allergy immunotherapy (SLIT) regulatory update

March 10, 2017 7:39 PM UTC

FDA approved a BLA for ALK-Abello’s HDM SLIT to treat HDM-induced rhinitis with or without conjunctivitis. ALK-Abello said the launch of the immunotherapy is “likely looking towards 2018.” Last year, ...

BCIQ Company Profiles

ALK-Abello A/S